VolitionRX LtdVNRX
Price$0.26

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value Insufficient data for a value estimatebased on filings through 30 Jun 2026
Market Price $0.26Price as of 30 Sep 2026
Data confidenceNot applicable

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 5.0% (near-term consensus, capped) · years 2–5: 73.9%/yr (balance of the path).57.2% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 663.1%Yr 752.3%Yr 841.6%Yr 930.8%Yr 1020.0%
73.9% → 20.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 1118.3%Yr 1216.6%Yr 1314.9%Yr 1413.2%Yr 1511.5%Yr 169.8%Yr 178.1%Yr 186.4%Yr 194.7%Yr 203.0%
20.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Discount rate (cost of equity) 9.9%
Volatility vs market (adjusted beta)1.10

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetVolitionRX LtdVNRXHealth Care
Valuation
P/E—
P/S3.0×
P/B—
EV / Revenue4.7×
EV / EBITDA—
Profitability
Gross margin100.0%
Operating margin-791.2%
Net margin-1,043.1%
FCF margin-796.7%
Returns
ROE—
ROA-308.9%
ROIC—
Growth
Revenue growth (YoY)99.3%
5-yr fwd EPS growth57.2%
Financial strength
Debt / Equity—
Current ratio0.30×
Altman Z-Score-53.8
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.